These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 10963376

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome.
    Jarnagin WR, Klimstra DS, Hezel M, Gonen M, Fong Y, Roggin K, Cymes K, DeMatteo RP, D'Angelica M, Blumgart LH, Singh B.
    J Clin Oncol; 2006 Mar 01; 24(7):1152-60. PubMed ID: 16505435
    [Abstract] [Full Text] [Related]

  • 7. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
    Kim SJ, Akita M, Sung YN, Fujikura K, Lee JH, Hwang S, Yu E, Otani K, Hong SM, Zen Y.
    Am J Surg Pathol; 2018 Apr 01; 42(4):512-521. PubMed ID: 29309301
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.
    Schlitter AM, Born D, Bettstetter M, Specht K, Kim-Fuchs C, Riener MO, Jeliazkova P, Sipos B, Siveke JT, Terris B, Zen Y, Schuster T, Höfler H, Perren A, Klöppel G, Esposito I.
    Mod Pathol; 2014 Jan 01; 27(1):73-86. PubMed ID: 23828315
    [Abstract] [Full Text] [Related]

  • 11. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P, Christodoulou P, Kapralos P, Exarchakos M, Bisbiroula A, Hadjiyannakis M, Georgountzos C, Thomas-Tsagli E.
    Pathol Res Pract; 1997 Jan 01; 193(11-12):767-75. PubMed ID: 9521509
    [Abstract] [Full Text] [Related]

  • 12. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas.
    Kanavaros P, Bai M, Stefanaki K, Poussias G, Rontogianni D, Zioga E, Gorgoulis V, Agnantis NJ.
    Histol Histopathol; 2001 Apr 01; 16(2):377-86. PubMed ID: 11332692
    [Abstract] [Full Text] [Related]

  • 13. [Relationship between genetic alterations and clinicopathological features in intrahepatic cholangiocarcinoma].
    Cong W, Finkelstein SD, Wu M.
    Zhonghua Bing Li Xue Za Zhi; 2001 Jun 01; 30(3):183-7. PubMed ID: 11866974
    [Abstract] [Full Text] [Related]

  • 14. [TP53 gene aberrations in chondromatous neoplasms: correlation with immunohistochemical p53 accumulation and MDM2 expression].
    Blasenbreu S, Baretton GB, Bender C, Haas CJ, Diebold J, Löhrs U.
    Verh Dtsch Ges Pathol; 1998 Jun 01; 82():284-9. PubMed ID: 10095448
    [Abstract] [Full Text] [Related]

  • 15. MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma.
    Li H, Zhou ZQ, Yang ZR, Tong DN, Guan J, Shi BJ, Nie J, Ding XT, Li B, Zhou GW, Zhang ZY.
    Hepatology; 2017 Jul 01; 66(1):136-151. PubMed ID: 28194813
    [Abstract] [Full Text] [Related]

  • 16. p53 Mutations in human cholangiocarcinoma: a review.
    Khan SA, Thomas HC, Toledano MB, Cox IJ, Taylor-Robinson SD.
    Liver Int; 2005 Aug 01; 25(4):704-16. PubMed ID: 15998419
    [Abstract] [Full Text] [Related]

  • 17. Proliferative index facilitates distinction between benign biliary lesions and intrahepatic cholangiocarcinoma.
    Tsokos CG, Krings G, Yilmaz F, Ferrell LD, Gill RM.
    Hum Pathol; 2016 Nov 01; 57():61-67. PubMed ID: 27396933
    [Abstract] [Full Text] [Related]

  • 18. Abnormal expression of MDM2 in prostate carcinoma.
    Leite KR, Franco MF, Srougi M, Nesrallah LJ, Nesrallah A, Bevilacqua RG, Darini E, Carvalho CM, Meirelles MI, Santana I, Camara-Lopes LH.
    Mod Pathol; 2001 May 01; 14(5):428-36. PubMed ID: 11353053
    [Abstract] [Full Text] [Related]

  • 19. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
    Hao XY, Cai JP, Liu X, Chen W, Hou X, Chen D, Lai JM, Liang LJ, Yin XY.
    Chin J Cancer; 2016 Jul 28; 35(1):70. PubMed ID: 27469137
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.